|
Clinical efficacy of milnacipran: placebo-controlled
trials.
Lecrubier Y, Pletan Y,
Solles A, Tournoux A, Magne V.
INSERM U302
Hopital Pitie-Salpetriere
Paris, France.
Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:29-33.
Abstract
The clinical efficacy of milnacipran, a
selective serotonin and noradrenaline reuptake inhibitor, was reviewed on
the basis of three, multicentre, placebo-controlled trials in major
depression. A dose-range study showed the superiority of milnacipran at 50
or 100 mg twice a day compared with placebo whereas the effect of 25 mg
twice a day was not clearly distinguished from that of placebo. This has
been confirmed by other studies where the 50-mg twice-a-day regimen was
shown to be significantly more efficacious than placebo on all outcome
measures (Hamilton Depression Rating Scale, Montgomery-Asberg Depression
Rating Scale, Clinical Global Impression). The positive results in the
individual studies were supported by a meta-analysis of the data from the
three studies. A subgroup analysis of hospitalized patients in the
meta-analysis showed an advantage for milnacipran, suggesting that
milnacipran is effective in more severe depression.
|
